SCHEMBL21484853

SCHEMBL21484853

COc1cccnc1-c1csc(NC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
CSNK2A1 P68400 5/20 0.54
KDM4E B2RXH2 3/20 0.53
EGFR P00533 5/20 0.52
BLM P54132 2/20 0.51
USP2 O75604 1/20 0.51
NSD2 O96028 1/20 0.51
ALPL P05186 1/20 0.51
POLB P06746 1/20 0.51
ALPI P09923 1/20 0.51
ALPG P10696 1/20 0.51
APOBEC3G Q9HC16 1/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
ERBB2 P04626 3/20 0.50
CSNK2A2 P19784 1/20 0.49
CSNK2B P67870 1/20 0.49
CSNK2A3 Q8NEV1 1/20 0.49
SRPK1 Q96SB4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484885 0.89 EGFR (0.60) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484597 0.87 MEN1 (0.53) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484804 0.83 CSNK2A1 (0.57) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484598 0.83 MRE11 (0.57) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484653 0.83 EGFR (0.56) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484721 0.82 MRE11 (0.59) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484860 0.81 EGFR (0.59) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484802 0.81 CSNK2A1 (0.51) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484889 0.80 EGFR (0.54) MEN1KMT2ACSNK2A1KDM4EEGFR
SCHEMBL21484629 0.80 EGFR (0.62) MEN1KMT2ACSNK2A1KDM4EEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885CSNK2A1 2033/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885CSNK2A1 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.